These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24135217)

  • 1. Vitamin D deficiency: consequence or cause of CKD?
    de Boer IH; Thadhani R
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1844-6. PubMed ID: 24135217
    [No Abstract]   [Full Text] [Related]  

  • 2. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
    Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 4. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

  • 5. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE.
    Lovshin JA; Cherney DZ
    Hypertens Res; 2014 Jan; 37(1):4-6. PubMed ID: 24026039
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch S
    Int J Clin Pract; 2010 Sep; 64(10):1337-40. PubMed ID: 20716140
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J
    Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
    [No Abstract]   [Full Text] [Related]  

  • 10. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
    Ritz E
    MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetes complications and the renin-angiotensin system.
    Perkins BA; Aiello LP; Krolewski AS
    N Engl J Med; 2009 Jul; 361(1):83-5. PubMed ID: 19571288
    [No Abstract]   [Full Text] [Related]  

  • 12. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
    Hollenberg NK; Epstein M
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevalence of anemia in patients with type II diabetes and mild to moderate chronic kidney disease and the impact of anti-RAS medications.
    Dousdampanis P; Trigka K; Fourtounas C
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):552-7. PubMed ID: 24821151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum potassium in dual renin-angiotensin-aldosterone system blockade.
    Seliger SL; Fried LF
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):219-21. PubMed ID: 24408119
    [No Abstract]   [Full Text] [Related]  

  • 15. [Diabetic nephropathy and ACE inhibitors].
    Amann B
    Clin Res Cardiol; 2006 Jan; 95 Suppl 1():i83-7. PubMed ID: 16598556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of angiotensin inhibition.
    Nobakht N; Kamgar M; Rastogi A; Schrier RW
    Nat Rev Nephrol; 2011 Jun; 7(6):356-9. PubMed ID: 21502972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-receptor blockade in renal disease: the hard issues.
    Sica DA
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):469-71. PubMed ID: 15225107
    [No Abstract]   [Full Text] [Related]  

  • 20. Kidney disease in diabetology: lessons from 2008.
    Schernthaner G
    Nephrol Dial Transplant; 2009 Feb; 24(2):396-9. PubMed ID: 19144896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.